Skip to main content

Boehringer Ingelheim Buys Cellomics Automated Cell Imaging Technology

NEW YORK, Aug. 3 – Cellomics has sold its ArrayScan HCS system for imaging cells to Boehringer Ingelheim Pharmaceuticals, Cellomics said on Friday.

The giant German pharma company will use the system to automate its drug-discovery process, the company said in a statement.

Financial details were not disclosed.

The HCS system analyzes how potential drugs affect cells by automatically imaging whether cellular probes fluoresce. The system, which Cellomics said has been placed in nine of the top 10 pharmaceutical companies in the world, is compatible with both 96 and 384 well microtitre plates.

In addition to ArrayScan, Cellomics is also developing other screening and bioinformatics products for cell analysis.  

“Cellomics is very proud to have placed an ArrayScan HCS system in the lab or such a well-respected company,” Cellomics Vice President for Sales Paul Kinnon said in the statement.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.